158 related articles for article (PubMed ID: 38170955)
1. Reactivation of previously controlled Vogt-Koyanagi-Harada disease more than 46 years following COVID-19 vaccination: a case study.
Muto T; Sakamoto M; Imaizumi S; Kamoi K
J Int Med Res; 2024 Jan; 52(1):3000605231221081. PubMed ID: 38170955
[TBL] [Abstract][Full Text] [Related]
2. Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination.
Accorinti M; Saturno MC; Manni P
Ocul Immunol Inflamm; 2022 Jul; 30(5):1228-1233. PubMed ID: 35201950
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease.
Feng H; Chen W; Yang J; Kong H; Li H; He Y; Wang H
BMC Ophthalmol; 2024 Jun; 24(1):238. PubMed ID: 38849758
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
5. Vogt-Koyanagi-Harada disease after SARS-CoV-2 infection: Case report and literature review.
Zou H; Zhang K; Chen X; Sha S
Immun Inflamm Dis; 2024 Apr; 12(4):e1250. PubMed ID: 38661242
[TBL] [Abstract][Full Text] [Related]
6. A case of probable Vogt-Koyanagi-Harada disease in a 3-year-old girl.
Katsuyama A; Kusuhara S; Awano H; Nagase H; Matsumiya W; Nakamura M
BMC Ophthalmol; 2019 Aug; 19(1):179. PubMed ID: 31409322
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids.
Nakayama M; Keino H; Watanabe T; Okada AA
Br J Ophthalmol; 2019 Feb; 103(2):274-278. PubMed ID: 29666121
[TBL] [Abstract][Full Text] [Related]
8. Vogt-Koyanagi-Harada Disease following mRNA-1273 (Moderna) COVID-19 Vaccination.
Joo CW; Kim YK; Park SP
Ocul Immunol Inflamm; 2022 Jul; 30(5):1250-1254. PubMed ID: 35404752
[TBL] [Abstract][Full Text] [Related]
9. Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine.
De Domingo B; López M; Lopez-Valladares M; Ortegon-Aguilar E; Sopeña-Perez-Argüelles B; Gonzalez F
Cells; 2022 Mar; 11(6):. PubMed ID: 35326462
[TBL] [Abstract][Full Text] [Related]
10. The spectrum of Vogt-Koyanagi-Harada disease in South India.
Murthy SI; Moreker MR; Sangwan VS; Khanna RC; Tejwani S
Int Ophthalmol; 2007; 27(2-3):131-6. PubMed ID: 17318321
[TBL] [Abstract][Full Text] [Related]
11. Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease.
Xu K; Gao B; Li J; Xiang Y; Cao L; Zhao M
Hum Vaccin Immunother; 2023 Aug; 19(2):2220630. PubMed ID: 37282614
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of patients with acute Vogt-Koyanagi-Harada disease treated with intravenous corticosteroid pulse followed by the slow tapering of oral corticosteroid therapy.
Fushitsu R; Ishibazawa A; Murono M; Kinouchi R
Int Ophthalmol; 2023 Feb; 43(2):431-440. PubMed ID: 35869402
[TBL] [Abstract][Full Text] [Related]
13. Vogt-koyanagi-harada disease with onset in elderly patients aged 68 to 89 years.
Yamamoto Y; Fukushima A; Nishino K; Koura Y; Komatsu T; Ueno H
Jpn J Ophthalmol; 2007; 51(1):60-3. PubMed ID: 17295144
[TBL] [Abstract][Full Text] [Related]
14. Vogt Koyanagi Harada disease following a recent COVID-19 infection.
Anthony E; Rajamani A; Baskaran P; Rajendran A
Indian J Ophthalmol; 2022 Feb; 70(2):670-672. PubMed ID: 35086262
[TBL] [Abstract][Full Text] [Related]
15. Acute phase clinical manifestations of patients with Vogt-Koyanagi-Harada disease in Southern China.
Zhang C; Wang Y; Chen Y; Zhou H; Hong Q; Yu X; Ng TK; Cen LP
BMC Ophthalmol; 2023 May; 23(1):199. PubMed ID: 37147563
[TBL] [Abstract][Full Text] [Related]
16. Bilateral acute angle closure glaucoma as an initial presentation of Vogt-Koyanagi-Harada syndrome: A clinical case report.
Yuan F; Zhang Y; Yan X
Eur J Ophthalmol; 2022 Jan; 32(1):NP230-NP234. PubMed ID: 32811185
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease occurred during pregnancy.
Alromaih AZ; Almater AI; Albloushi AF; Alkheraiji NF; Abu El-Asrar AM
Int Ophthalmol; 2023 Jan; 43(1):185-195. PubMed ID: 35945413
[TBL] [Abstract][Full Text] [Related]
18. Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality.
Herbort CP; Abu El Asrar AM; Yamamoto JH; Pavésio CE; Gupta V; Khairallah M; Tugal-Tutkun I; Soheilian M; Takeuchi M; Papadia M
Int Ophthalmol; 2017 Dec; 37(6):1383-1395. PubMed ID: 27844182
[TBL] [Abstract][Full Text] [Related]
19. Chronic Recurrent Vogt-Koyanagi-Harada Disease and Development of 'Sunset Glow Fundus' Predict Worse Retinal Sensitivity.
Abu El-Asrar AM; Al Mudhaiyan T; Al Najashi AA; Hemachandran S; Hariz R; Mousa A; Al-Muammar A
Ocul Immunol Inflamm; 2017 Aug; 25(4):475-485. PubMed ID: 27003480
[TBL] [Abstract][Full Text] [Related]
20. Vogt-Koyanagi-Harada disease developed during chemotherapy for Hodgkin lymphoma: a case report.
Koyama M; Nishijima E; Honda T; Gonmori-Ohta C; Sasamoto T; Tanaka K; Watanabe A; Nakano T; Akiyama M
BMC Ophthalmol; 2024 Mar; 24(1):115. PubMed ID: 38481205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
